Literature DB >> 19559518

The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed?

Marco Roscigno1, Shahrokh F Shariat, Vitaly Margulis, Pierre Karakiewicz, Mesut Remzi, Eiji Kikuchi, Richard Zigeuner, Alon Weizer, Arthur Sagalowsky, Karim Bensalah, Jay D Raman, Christian Bolenz, Wassim Kassou, Theresa M Koppie, Christopher G Wood, Jeffrey Wheat, Cord Langner, Casey K Ng, Umberto Capitanio, Roberto Bertini, Mario I Fernández, Shuji Mikami, Masaru Isida, Philipp Ströbel, Francesco Montorsi.   

Abstract

BACKGROUND: The role and extent of lymphadenectomy in patients with upper-tract urothelial carcinoma (UTUC) is debated.
OBJECTIVE: To establish whether the number of lymph nodes (LNs) removed might be associated with better cause-specific survival in patients with UTUC. DESIGN, SETTING, AND PARTICIPANTS: The study included 552 consecutive patients who underwent radical nephroureterectomy (RNU) and lymphadenectomy between 1992 and 2006. INTERVENTION: Patients were treated with RNU and lymphadenectomy. MEASUREMENTS: Univariable and multivariable Cox proportional hazards regression models addressed the association between the number of LNs removed and cause-specific mortality (CSM). The number of LNs removed was coded as a cubic spline to allow for nonlinear effects. Finally, the most informative cut-off for the number of removed LNs was identified. RESULTS AND LIMITATIONS: In the entire population, the number of LNs removed was not associated with CSM in univariable (hazard ratio [HR]: 0.99; p=0.16) or in multivariable (HR: 0.97; p=0.12) analyses. In contrast, in the subgroup of pN0 patients (n=412), the number of LNs removed achieved the independent predictor status of CSM (HR: 0.93; p=0.02). Eight LNs removed was the most informative cut-off in predicting CSM (HR: 0.42; p=0.004). The inclusion of the variable defining dichotomously the number of removed LNs (< 8 vs > or = 8) in the base model (age, Eastern Cooperative Oncology Group performance status, pathologic stage, grade, architecture, and lymphovascular invasion) significantly increased the accuracy in predicting CSM (+1.7%; p<0.001).
CONCLUSIONS: The extension of the lymphadenectomy in pN0 UTUC patients seems to be associated with CSM. Longer survival was observed in patients in whom at least eight LNs had been removed.

Entities:  

Mesh:

Year:  2009        PMID: 19559518     DOI: 10.1016/j.eururo.2009.06.004

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  42 in total

1.  Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma.

Authors:  Ricardo L Favaretto; Shahrokh F Shariat; Caroline Savage; Guilherme Godoy; Daher C Chade; Matthew Kaag; Bernard H Bochner; Jonathan Coleman; Guido Dalbagni
Journal:  BJU Int       Date:  2011-06-01       Impact factor: 5.588

2.  Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract.

Authors:  Piotr Zareba; Barak Rosenzweig; Andrew G Winer; Jonathan A Coleman
Journal:  Cancer       Date:  2017-02-02       Impact factor: 6.860

3.  Lymph node dissection could bring survival benefits to patients diagnosed with clinically node-negative upper urinary tract urothelial cancer: a population-based, propensity score-matched study.

Authors:  Fan Dong; Tianyuan Xu; Xianjin Wang; Yifan Shen; Xiaohua Zhang; Shanwen Chen; Shan Zhong; Minguang Zhang; Qiang Ding
Journal:  Int J Clin Oncol       Date:  2018-10-17       Impact factor: 3.402

4.  Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: multi-institutional large retrospective study JCOG1110A.

Authors:  Junichi Inokuchi; Kentaro Kuroiwa; Yoshiyuki Kakehi; Mikio Sugimoto; Toshiki Tanigawa; Hiroyuki Fujimoto; Momokazu Gotoh; Naoya Masumori; Osamu Ogawa; Masatoshi Eto; Chikara Ohyama; Akito Yamaguchi; Hideyasu Matsuyama; Tomohiko Ichikawa; Tomohiko Asano; Junki Mizusawa; Junko Eba; Seiji Naito
Journal:  World J Urol       Date:  2017-05-15       Impact factor: 4.226

Review 5.  Predictive tools for clinical decision-making and counseling of patients with upper tract urothelial carcinoma.

Authors:  Evanguelos Xylinas; Luis Kluth; Sibani Mangal; Morgan Roupret; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  World J Urol       Date:  2012-09-18       Impact factor: 4.226

6.  Mining the data on UTUC management.

Authors:  Michael J Leveridge
Journal:  Can Urol Assoc J       Date:  2012-12       Impact factor: 1.862

7.  Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma.

Authors:  Sima Porten; Arlene O Siefker-Radtke; Lianchun Xiao; Vitaly Margulis; Ashish M Kamat; Christopher G Wood; Eric Jonasch; Colin P N Dinney; Surena F Matin
Journal:  Cancer       Date:  2014-03-13       Impact factor: 6.860

Review 8.  Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.

Authors:  Andrea B Apolo; Vanessa Hoffman; Matthew G Kaag; David M Latini; Cheryl T Lee; Jonathan E Rosenberg; Margaret Knowles; Dan Theodorescu; Bogdan A Czerniak; Jason A Efstathiou; Matthew L Albert; Srikala S Sridhar; Vitaly Margulis; Surena F Matin; Matthew D Galsky; Donna Hansel; Ashish M Kamat; Thomas W Flaig; Angela B Smith; Edward Messing; Diane Zipursky Quale; Yair Lotan
Journal:  Urol Oncol       Date:  2014-07-25       Impact factor: 3.498

9.  Current Status of Lymphadenectomy During Radical Nephroureterectomy for Upper Tract Urothelial Cancer-Yes, No or Maybe?

Authors:  Ashwin Sunil Tamhankar; Saurabh Ramesh Patil; Puneet Ahluwalia; Gagan Gautam
Journal:  Indian J Surg Oncol       Date:  2018-08-13

10.  Template-based lymphadenectomy reduces the risk of regional lymph node recurrence among patients with upper/middle ureteral cancer.

Authors:  Tsunenori Kondo; Isao Hara; Toshio Takagi; Yoshiki Kodama; Yasunobu Hashimoto; Hirohito Kobayashi; Junpei Iizuka; Kenji Omae; Kazuhiko Yoshida; Kazunari Tanabe
Journal:  Int J Clin Oncol       Date:  2016-07-23       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.